Torrent Pharmaceuticals share news, announcements and annual reports
NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap
Torrent Pharmaceuticals Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Nov 2002 on NSE
Last close ₹4,595.00down ₹18.40 (0.40%)BSE ₹4,585.10
Share price at the NSE close on 2 Nov 2026. Previous close ₹4,613.40.
2 Nov: open ₹4,636.50, high ₹4,675.00, low ₹4,553.00
52-week range of traded prices to 2 Nov 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,74,779 Cr61st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 82.29
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.51
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.83%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.76
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,55,93552.5% delivered
Torrent Pharmaceuticals share news and announcements
865 announcements, routine notices left out, newest first. Page 10 of 18.
Jan 2020
15 Jan · Corporate action
Dec 2019
Nov 2019
15 Nov · Related Party Transactions
4 Nov · Updates
Oct 2019
23 Oct · Results
18 Oct · Analysts
16 Oct · Analysts
14 Oct · Board meeting
Sep 2019
23 Sep · Redemption
16 Sep · Issue of Securities
16 Sep · Redemption
11 Sep · Rating
Aug 2019
12 Aug · Updates
Jul 2019
25 Jul · Meeting
23 Jul · Board meeting
23 Jul · Management
23 Jul · Results
23 Jul · Meeting
17 Jul · Updates
15 Jul · Analysts
10 Jul · Board meeting
Jun 2019
18 Jun · Related Party Transactions
May 2019
23 May · Legal
Exchange has sought clarification from Torrent Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. The response of the Company is awaited.22 May · Corporate action
20 May · Management
20 May · Board meeting
20 May · Dividend
20 May · Results
18 May · Updates
8 May · Analysts
4 May · Updates
Apr 2019
26 Apr · Updates